Keywords: دنوزوماب، دنوسوماب; Denosumab; Zoledronic acid; Teriparatide; Bone remodeling; Wnt-inhibitors; Myostatin;
مقالات ISI دنوزوماب، دنوسوماب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: دنوزوماب، دنوسوماب; Chemotherapy; Denosumab; Dysphagia; Giant cell tumour; Larynx;
Keywords: دنوزوماب، دنوسوماب; Denosumab; Diffuse sclerosing osteomyelitis; Jaw osteonecrosis; MRONJ; Antiresorptive treatment; Osteoclast;
Keywords: دنوزوماب، دنوسوماب; Bone-related minerals; Denosumab; Osteoporosis; Rheumatoid arthritis;
Keywords: دنوزوماب، دنوسوماب; Antiresorptive medications; Bisphosphonates; Denosumab; Surgical therapy;
Keywords: دنوزوماب، دنوسوماب; Bone metastasis; Bisphosphonate; Breast cancer; Cancer treatment-induced bone loss; Denosumab; Zoledronic acid;
Keywords: دنوزوماب، دنوسوماب; Acute kidney injury; Immunoallergic intertistial nephritis; Denosumab; Monoclonal antibodies;
Keywords: دنوزوماب، دنوسوماب; Osteoporosis; Fracture; Denosumab; Drug holiday;
Keywords: دنوزوماب، دنوسوماب; Bisphosphonates; Denosumab; Systematic review; Animal; Rodents;
Keywords: دنوزوماب، دنوسوماب; abiraterone; bone-targeted agents; castration-resistant prostate cancer; denosumab; electronic health records; enzalutamide; zoledronic acid;
Keywords: دنوزوماب، دنوسوماب; Osteoporosis; Denosumab; Fragility fracture; HR-pQCT;
Keywords: دنوزوماب، دنوسوماب; Prostate cancer; Bisphosphonates; Abiraterone acetate; Denosumab; Zoledronic acid; Enzalutamide; Radium-223;
Keywords: دنوزوماب، دنوسوماب; Medication-related osteonecrosis of the jaw (MRONJ); Denosumab; Bisphosphonates; Side effect; Skeletal-related events (SREs);
Keywords: دنوزوماب، دنوسوماب; Giant cell tumor; Ischium; Magnetic resonance imaging (MRI); Computed tomography (CT); Denosumab;
Keywords: دنوزوماب، دنوسوماب; Denosumab; Lactation; Osteoporosis; Pregnancy; Teriparatide;
Keywords: دنوزوماب، دنوسوماب; Denosumab; Zoledronic acid; Bone metastases; Gastrointestinal cancer; Pancreas-biliary system cancer; Rare cancers;
Keywords: دنوزوماب، دنوسوماب; MRONJ; osteonecrosis; risk factors; treatment; bisphosphonates; denosumab;
Keywords: دنوزوماب، دنوسوماب; Bone marrow oedema; Anti-resorptive therapy; Denosumab; Magnetic resonance imaging; Bone turnover;
Keywords: دنوزوماب، دنوسوماب; RANK; receptor activator of nuclear factor kappa-B; HSA; hip structural analysis; BMD; bone mineral density; FREEDOM; Fracture Reduction Evaluation of Denosumab in Osteoporosis every 6Â Months; DIRECT; Denosumab fracture Intervention Randomized placebo Co
Keywords: دنوزوماب، دنوسوماب; Bone mineral density; bone-targeted therapy; denosumab; prostate cancer; radium-223; zoledronic acid;
Keywords: دنوزوماب، دنوسوماب; Osteoporosis; Denosumab; Bone mineral density; Bone-specific alkaline phosphatase; Tartrate-resistant acid phosphatase 5b;
Keywords: دنوزوماب، دنوسوماب; Giant cell tumor; Denosumab; RANKL; Malignancy in giant cell tumor; Neoadjuvant;
Keywords: دنوزوماب، دنوسوماب; Breast neoplasms; Registries; Cohort studies; Outpatients; Outcome assessment; Bone metastasis; Diphosphonates; Denosumab;
Keywords: دنوزوماب، دنوسوماب; Denosumab; RANK ligand; Osteoporosis; Fracture; Drug safety;
Keywords: دنوزوماب، دنوسوماب; Bisphosphonates; Denosumab; Raloxifene; Teriparatide; Atypical femoral fractures; Osteonecrosis of the jaw;
Keywords: دنوزوماب، دنوسوماب; Skeletal-related events; Bone metastases; Advanced cancer; Denosumab; Bisphosphonates; Imaging;
Keywords: دنوزوماب، دنوسوماب; Skeletal-related event; Denosumab; Zoledronic acid; Bone metastases; Meta- analysis;
Keywords: دنوزوماب، دنوسوماب; Bisphosphonates; Bone; Cancer; Denosumab; Metastatic; Pain; Quality of life;
Keywords: دنوزوماب، دنوسوماب; AI; aromatase inhibitor; BMD; bone mineral density; BMI; body mass index; Bone; Breast cancer; Chemotherapy; Multiple myeloma; Prostate cancer; Denosumab; Zoledronic acid;
Keywords: دنوزوماب، دنوسوماب; MRONJ; Osteonecrosis; Bisphosphonates; Denosumab; Sunitinib;
Keywords: دنوزوماب، دنوسوماب; Crizotinib; denosumab; fertility preservation; ovarian stimulation; targeted cancer treatment;
Keywords: دنوزوماب، دنوسوماب; Giant cell tumor; Cervical spine; Denosumab; Conservative treatment
Keywords: دنوزوماب، دنوسوماب; Giant Cell Tumor; Radiological Features; Denosumab
Keywords: دنوزوماب، دنوسوماب; anti-resorptive drugs; bisphosphonate-related osteonecrosis of the jaw; Denosumab; membranes; platelet concentrates; platelet-rich fibrin;
Keywords: دنوزوماب، دنوسوماب; Skeletal-related events; Metastatic breast cancer; Bisphosphonates; Denosumab;
Keywords: دنوزوماب، دنوسوماب; Osteonecrosis; Bisphosphonate; Denosumab; MRONJ; BRONJ; Bone fluorescence
Keywords: دنوزوماب، دنوسوماب; Monoclonal antibodies; Multiple myeloma; Bone disease; Daratumumab; Elotuzumab; Siltuximab; Lorvotuzumab; Pembrolizumab; Denosumab; BHQ880
Keywords: دنوزوماب، دنوسوماب; Adjuvant therapy; Denosumab; Giant cell tumor; Mobile spine; Sacrum; Spine tumor;
Keywords: دنوزوماب، دنوسوماب; Bisphosphonates; Denosumab; Lung cancer; Bone metastases; Bone targeted therapy;
Keywords: دنوزوماب، دنوسوماب; Bisphosphonates; Denosumab; Osteonecrosis; Surgery; Recurrence;
Keywords: دنوزوماب، دنوسوماب; Postmenopausal Osteoporosis; Long-term-Treatment; Bisphosphonate; Denosumab; Romosozumab; Cathepsin K;
Keywords: دنوزوماب، دنوسوماب; Denosumab; Hypocalcemia; Metastatic prostate cancer; Osteoclast; RANKL; Skeletal-related event;
Keywords: دنوزوماب، دنوسوماب; Central giant cell granuloma; Denosumab; Medical therapies
Keywords: دنوزوماب، دنوسوماب; Antiangiogenic therapy; Vascular endothelial growth factor inhibitors; Tyrosine kinase inhibitors; Mammalian target of rapamycin inhibitors; Nitrogen-containing bisphosphonates; Receptor activator of nuclear factor-κB ligand inhibitors; Denosumab;
Keywords: دنوزوماب، دنوسوماب; Denosumab; Proximal femur strength; Vertebral body strength; FEA; QCT;
Keywords: دنوزوماب، دنوسوماب; MRONJ; Bisphosphonate; Denosumab; Oral surgery; Maxillofacial surgery; BRONJ;
Keywords: دنوزوماب، دنوسوماب; Bisphosphonates; Denosumab; Antiremodeling agents; ONJ;
Keywords: دنوزوماب، دنوسوماب; Denosumab; Hypercalcemia; Multiple myeloma; Renal dysfunction; RANK ligand inhibitor;
Keywords: دنوزوماب، دنوسوماب; Breast cancer; Osteoporosis; Fractures; Aromatase inhibitors; Screening; Bisphosphonates; Denosumab;
Keywords: دنوزوماب، دنوسوماب; RANKL-inhibitor; Xgeva; Denosumab; Osteonecrosis of the jaw; ONJ; Bisphosphonate; BRONJ; Bone turnover; Bone scan; Bone scintigraphy; Pathogenesis